CVA Family Office’s Adaptive Biotechnologies ADPT Stock Holding History

CVA Family Office’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$858	Hold	40	–	–	﹤0.01%	1664
2026 Q1	$555	Hold	40	–	–	﹤0.01%	1739
2025 Q4	$650	Hold	40	–	–	﹤0.01%	1166
2025 Q3	$598	Buy	+40	New	+$487	﹤0.01%	1211
2023 Q2	–	Sell	-425	Closed	-$3.75K	–	1014
2023 Q1	$3.75K	Hold	425	–	–	﹤0.01%	806
2022 Q4	$3.25K	Hold	425	–	–	﹤0.01%	782
2022 Q3	$3K	Hold	425	–	–	﹤0.01%	763
2022 Q2	$3K	Buy	425 +275	+183%	+$2.42K	﹤0.01%	782
2022 Q1	$2K	Sell	150 -40	-21%	-$629	﹤0.01%	858
2021 Q4	$5K	Buy	+190	New	+$5.82K	﹤0.01%	737
2021 Q3	–	Sell	-40	Closed	-$2K	–	363
2021 Q2	$2K	Buy	+40	New	+$1.55K	﹤0.01%	862

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

CVA Family Office's ADPT Position: Q2 2026 in Review

CVA Family Office held its Adaptive Biotechnologies (ADPT) position steady in Q2 2026 at 40 shares worth $858. The position accounts for ﹤0.01% of the portfolio, ranked #1664.

CVA Family Office first reported a position in ADPT in Q2 2021 and has held it in 11 quarters since. The position peaked at $5K in Q4 2021. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

CVA Family Office held 40 shares of Adaptive Biotechnologies worth $858 as of Q2 2026.
CVA Family Office left its Adaptive Biotechnologies share count unchanged in Q2 2026.
Adaptive Biotechnologies made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1664 holding.
CVA Family Office first reported a position in Adaptive Biotechnologies in Q2 2021 and has held it in 11 quarters since.
CVA Family Office's Adaptive Biotechnologies position peaked at $5K in Q4 2021.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.